Oncolytics Biotech's Pelareorep Selected for Inclusion in Precision Promise Pivotal Phase 3 Platform Trial

Oncolytics Biotech has announced that its drug, pelareorep, has been selected for inclusion in Precision PromiseSM, a Phase 3 clinical trial designed to evaluate the drug in combination with checkpoint inhibitors and chemotherapeutic agents gemcitabine and nab-paclitaxel. The trial is expected to support approval of the studied combination as a treatment for first-line metastatic pancreatic duct..